摘要
目的考察厄贝沙坦治疗糖尿病肾病的临床疗效及其肾保护作用。方法将86例患者随机分为观察组和对照组各43例,观察组视患者病情给予个体化的降糖降脂治疗,并在合理口服降糖药与注射胰岛素的同时,帮助其严格控制饮食,指导开展一定程度的体能锻炼,尽量将HbAle控制在6.5%的范围内,观察组在对照组基础上加用厄贝沙坦口服进行治疗。结果两组患者治疗后的HbAle、TP及SCr水平均较治疗前显著降低(P<0.05),且观察组改善程度较对照组更为理想(P<0.05);两组患者治疗后的sICAM-1与sVCAM-1均较治疗前显著降低(P<0.05),且观察组改善效果显著优于对照组(P<0.05);观察组总有效率为93.0%,对照组总有效率为74.4%,观察组临床疗效显著优于对照组,比较有统计学意义(P<0.05)。结论厄贝沙坦治疗DN临床疗效满意,同时具较好保护的作用,有利于DN病情的延缓和治愈,值得临床推广应用。
Objective To investigate the clinical curative effect and the renal protective effect of irbesartan in treatment of diabetic nephropathy. Methods 86 patients were randomly divided into the observation group and 43 cases in the control group, the observation group treated with hypoglycemic lipid-lowering therapy was individualized, and within reasonable oral hypoglycemic agents and insulin injections at the same time, help to control its strict diet, physical exercise and guidance for the certain degree, as the HbAle control in 6.5% range, the observation group on the basis of the control group were treated with irbesartan orally. Results The two groups of patients after the treatment of HbAle, TP and SCr levels were significantly lower after treatment than before （P〈0,05）, and the observation group improved more than control group （P〈0.05）; for the ideal of sICAM-1 and sVCAM-1 of patients in the two groups after treatment than before treatment was significantly lower （P〈0.05）, and the observation group improved significantly better than the control group （P〈0.05）; total effective rate in the observation group was 93%, control group the total effective rate was 74.4%, the clinical curative effect of observation group was significantly better than the control group, there was significant difference （P〈0.05）. Conclusion Irbesartan treatment of DN clinical curative effect, at the same time with good protection role, is conducive to the severity of DN delay and cure, it is worthy of clinical application.
出处
《中国医药指南》
2013年第22期435-436,共2页
Guide of China Medicine
